Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach
Overall, these findings suggest Vγ9Vδ2 T cells as a promising "off-the-shelf" immunotherapy approach for AML patients, especially for patients with venetoclax-resistant disease.
Authors
- Maryam Siddiqui (ORCID: https://orcid.org/0000-0002-5425-1740)
- Amanda Eckstrom
- Abhishek Maiti
- Venkata Lokesh Battula (ORCID: https://orcid.org/0000-0001-5415-9058)
- Adishwar Rao (ORCID: https://orcid.org/0000-0003-1744-4217)
- Jianhua Zeng (ORCID: https://orcid.org/0000-0001-7557-2984)
- Jenny Borgman
- Anudishi Tyagi
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Virginia Commonwealth University (US)
- TauRx Pharmaceuticals (Singapore) (SG)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3390/cancers17193166
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Texas MD Anderson Cancer Center